On January 5, 2023, BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 m. BioVersys represents the first European-based investment of the AMR Action Fund.

Homburger advised BioVersys in this transaction. The Homburger team comprised Dieter Gericke and Thierry Burckhardt (both Corporate / M&A).

Contact

Nanding Susso / Marketing / [email protected]

January 11, 2023